Viewing Study NCT00193505


Ignite Creation Date: 2025-12-25 @ 3:30 AM
Ignite Modification Date: 2025-12-26 @ 2:12 AM
Study NCT ID: NCT00193505
Status: COMPLETED
Last Update Posted: 2011-05-03
First Post: 2005-09-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Sponsor: SCRI Development Innovations, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module